Core Insights - Elevance Health (NYSE: ELV) is scheduled to report earnings on July 17, 2025, with analysts projecting earnings of $9.19 per share on revenue of $48.26 billion, compared to $10.12 per share and $43.22 billion in the same quarter last year [3][4] Group 1: Stock Performance and Historical Data - Over the last five years, Elevance Health has experienced positive one-day stock returns in 55% of cases following earnings announcements, with a median positive return of 2.7% and a maximum return of 7.7% [3][7] - In the past five years, there have been 18 earnings data points, resulting in 11 positive and 7 negative one-day returns, leading to a positive return rate of approximately 61%, which increases to 73% when considering the last three years [7] Group 2: Financial Metrics - Elevance Health currently has a market capitalization of $77 billion and has generated $183 billion in revenue over the past twelve months, with a net income of $5.9 billion [4] Group 3: Trading Strategies - Traders can adopt two primary strategies around earnings announcements: pre-earnings positioning and post-earnings positioning, evaluating immediate and medium-term returns to inform trading actions [6] - A lower-risk strategy involves understanding the correlation between short-term and medium-term returns following earnings, allowing traders to take positions based on the strongest correlations observed [8][9]

Core Viewpoint - Elevance Health, Inc. (ELV) is expected to report its second-quarter 2025 results on July 17, 2025, with earnings estimated at $9.20 per share and revenues of $48.13 billion, reflecting an 11.4% year-over-year increase in revenues [1][6]. Financial Estimates - The second-quarter earnings estimate has declined by 1.8% over the past 60 days, indicating a year-over-year decline of 9.1% in earnings, while the revenue estimate suggests an 11.4% year-over-year increase [2]. - For the full year 2025, the revenue estimate stands at $195 billion, representing an 11.3% year-over-year increase, and the EPS estimate is $34.40, implying a 4.1% year-over-year increase [3]. Earnings Performance - Elevance has beaten the consensus estimate in three of the last four quarters, with an average surprise of negative 1.2% [3]. - The current Earnings ESP is 0.00%, and the Zacks Rank is 3 (Hold), indicating uncertainty regarding an earnings beat this quarter [4]. Revenue Drivers - The consensus estimate for product revenues indicates an 11.1% growth from the previous year's $5.5 billion, while premiums are expected to increase by 11.9% year-over-year [5]. - Growth in CarelonRx and recent acquisitions in home health and pharmacy services are anticipated to support revenue growth [8]. Expense Considerations - Elevated expenses are expected due to significant investments in digital capabilities, with total expenses projected to rise nearly 11% year-over-year [9]. - The benefit expense ratio is estimated at 88.4, higher than the previous year's 86.3, which may impact profit margins [9]. Segment Performance - The Health Benefits segment's operating income is expected to decrease by 12.4% year-over-year, with declining Medicaid memberships affecting premium growth [10].

Health insurer Elevance Health Inc. ELV is scheduled to release its second quarter 2025 financial results on July 17.Analysts estimate adjusted earnings of $9.197 per share on sales of $48.24 billion, as per data from Benzinga Pro.UnitedHealth Group Inc. UNH has been the first major health insurer to report quarterly earnings for several quarters. However, this quarter, the insurance giant will release its second quarter 2025 financial results on July 29.As it’s the biggest player in the industry, Forbes wr ...

Core Viewpoint - Analysts forecast that Elevance Health (ELV) will report quarterly earnings of $9.20 per share, indicating a year-over-year decline of 9.1%, while revenues are expected to reach $48.13 billion, reflecting an increase of 11.4% compared to the previous year [1] Revenue Estimates - The consensus estimate for 'Revenues- Premiums' is $39.62 billion, suggesting a year-over-year increase of 11.9% [5] - 'Revenues- Service fees' are expected to be $2.24 billion, indicating a decline of 1.8% year over year [5] - 'Revenues- Net investment income' is projected at $464.67 million, reflecting a decrease of 8.5% from the year-ago quarter [5] - 'Revenues- Product revenue' is forecasted to reach $6.14 billion, showing an increase of 11.1% from the previous year [6] Membership Estimates - 'Medical Membership - Medicare - Medicare Supplement' is expected to be 868.88 thousand, down from 894.00 thousand year over year [6] - 'Medical Membership - Commercial Risk-Based - Employer Group Risk-Based' is projected at 3.64 million, slightly down from 3.65 million in the same quarter last year [7] - 'Medical Membership - Commercial Risk-Based' is estimated at 5.00 million, up from 4.93 million year over year [7] - Total Medical Membership is expected to be 45.83 million, a slight increase from 45.78 million year over year [8] - 'Medical Membership - Medicare - Medicare Advantage' is projected to reach 2.24 million, up from 2.03 million year over year [8] - 'Medical Membership - Medicaid' is expected to be 8.86 million, down from 9.03 million year over year [9] - 'Medical Membership - Federal Employees Health Benefits' is projected at 1.65 million, slightly down from 1.66 million year over year [9] Stock Performance - Over the past month, shares of Elevance Health have returned -11.4%, contrasting with the Zacks S&P 500 composite's +4% change [9]

Core Insights - Elevance Health will be the first major health insurer to report its second quarter earnings, while competitors like UnitedHealth Group are facing challenges with higher-than-expected medical costs [4][5] - The report comes after Centene withdrew its 2025 financial guidance due to rising costs in its individual health plans and Medicaid [5][6] - Other companies, including Molina Healthcare and UnitedHealth, have also lowered earnings guidance or suspended financial outlooks due to cost pressures in government-subsidized health insurance programs [6][7] Company Overview - Elevance Health is the second largest health insurer in the U.S., with a diversified portfolio that includes commercial and government health insurance [9][10] - The company operates the Anthem brand Blue Cross and Blue Shield plans in 14 states and manages Medicaid through contracts with multiple states [10] - Elevance has a smaller Medicare Advantage business compared to UnitedHealth, with 2.3 million members, but has significant exposure to Medicaid and individual ACA coverage [11] Analyst Perspective - Analysts view Elevance positively due to its diverse member mix and balance between commercial and government businesses, as well as its brand recognition [12]

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the impact of Medicaid redetermination on the company's financial guidance and cost trends [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Elevance securities between April 18, 2024, and October 16, 2024, with a deadline for lead plaintiff applications set for July 11, 2025 [1]. - The defendants are accused of failing to disclose that the Medicaid redetermination process was leading to a significant rise in acuity and utilization of Medicaid members, contrary to their assurances to investors [3]. Financial Implications - Elevance's management claimed that premium rates negotiated with states were sufficient to manage the risks associated with Medicaid patients, despite rising Medicaid expenses [3]. - The lawsuit asserts that the financial guidance provided by Elevance did not accurately reflect the true impact of the redetermination process, leading to investor losses when the actual situation became known [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Elevance Health, Inc. common stock about the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Group 1: Class Action Details - Investors who purchased Elevance common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 11, 2025 [2]. - The lawsuit alleges that Elevance made false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. Group 2: Allegations Against Elevance - The lawsuit claims that Elevance misrepresented its monitoring of cost trends associated with the Medicaid redetermination process, assuring investors that premium rates were sufficient to address risks [4]. - It is alleged that the acuity and utilization of Elevance's Medicaid members rose significantly, contrary to the company's assurances, leading to damages for investors when the truth was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors by stating they were monitoring cost trends related to Medicaid "redetermination" processes and that premium rates were sufficient to cover rising costs [4]. - Contrary to these claims, the redetermination process led to a significant increase in Medicaid member utilization, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - Following a Q3 2024 earnings report on October 17, 2024, where Elevance missed EPS expectations by $1.33 (13.7%) due to elevated medical costs, the company lowered its EPS guidance for 2024 from $37.20 to $33.00 (11.3%), causing the stock price to decline by $52.61 per share, or 10.6%, to a closing price of $444.35 [7][8].

Core Viewpoint - The market anticipates Elevance Health (ELV) will report a year-over-year decline in earnings despite higher revenues in its upcoming earnings report for the quarter ended June 2025 [1] Earnings Expectations - Elevance Health is expected to post quarterly earnings of $9.20 per share, reflecting a year-over-year decrease of 9.1% [3] - Revenues are projected to reach $48.13 billion, representing an increase of 11.4% compared to the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - The Most Accurate Estimate for Elevance Health is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -5.05%, suggesting a bearish sentiment among analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [9][10] - A positive Earnings ESP combined with a Zacks Rank of 1, 2, or 3 has shown a nearly 70% success rate in predicting earnings beats [10] Historical Performance - In the last reported quarter, Elevance Health exceeded expectations by delivering earnings of $11.97 per share against an expected $11.21, resulting in a surprise of +6.78% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Conclusion - While Elevance Health does not currently appear to be a strong candidate for an earnings beat, investors should consider other influencing factors when making investment decisions ahead of the earnings release [17]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Financial Implications - Elevance claimed to be monitoring cost trends related to the Medicaid redetermination process and believed their negotiated rates were adequate [4]. - However, the redetermination process resulted in a significant increase in the acuity and utilization of Medicaid members, which was not reflected in Elevance's financial guidance for 2024 [5]. Group 4: Stock Performance - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a further decline in stock price by $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].